Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 227M | 274M | 257M | 273M | 304M |
| Gross Profit | 69M | 78M | 71M | 75M | 84M |
| Operating Income | -2M | -7M | 7M | 26M | 31M |
| EBITDA | 7M | 783K | 11M | 30M | 33M |
| Net Income | -6M | -7M | 5M | 21M | 24M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$1.75
-2.78% today
1Y Change
-44.79%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PetMed Express, Inc. (PETS) is a Healthcare stock with a market cap of $50.00M and listed on NASDAQ. The stock last traded around $1.75 and down 44.8% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -17.2%, EPS growth of +18.9%, a dividend yield of 0.0%. What stands out right now is revenue -17.2%, EPS +18.9%, free cash flow -103.6% with operating margin -17.4% and ROIC -94.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PETS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PETS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PETS Max Drawdown
-59.80%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PETS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$303.6M
+11.0% YoY
FY Net Income
$23.9M
+13.4% YoY
Free Cash Flow
$37.6M
+124.8% YoY
Revenue Growth
-17.2%
EPS Growth
+18.9%
Gross Margin
29.0%
Net Margin
-35.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 227M | 274M | 257M | 273M | 304M |
| Gross Profit | 69M | 78M | 71M | 75M | 84M |
| Operating Income | -2M | -7M | 7M | 26M | 31M |
| EBITDA | 7M | 783K | 11M | 30M | 33M |
| Net Income | -6M | -7M | 5M | 21M | 24M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 55M | 55M | 104M | 111M | 119M |
| Total Assets | 149M | 170M | 170M | 176M | 187M |
| Total Liabilities | 64M | 73M | 60M | 34M | 46M |
| Shareholder Equity | 85M | 97M | 110M | 142M | 141M |
| Total Debt | 996K | 1M | 995K | 0 | 0 |
| Net Debt | -54M | -54M | -103M | -111M | -119M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
40M
+116.6% YoY
Capital Expenditures
2M
-38.8% YoY
Free Cash Flow
38M
+124.8% YoY
Key ratios
Gross Margin
29.0%
Operating Margin
-17.4%
Net Margin
-35.5%
ROE
-122.1%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.